银屑病患者使用IL-23抑制剂与IL-17抑制剂的银屑病关节炎风险比较
本回顾性队列研究基于TriNetX数据库,纳入5490例成年银屑病患者并按倾向评分1:1匹配,比较初始使用IL-23抑制剂(IL23i)与IL-17抑制剂(IL17i)者后续发生银屑病关节炎(PsA)的风险。结果显示IL23i组5年PsA累积发生率显著低于IL17i组(11.68% vs 19.94%,P<0.001),IL23i治疗与PsA风险降低相关(HR 0.475;95%CI:0.382,0.590)。
要点
- IL23i组5年PsA累积发生率为11.68%,显著低于IL17i组的19.94%(P<0.001)。
- IL23i治疗与PsA风险降低相关(HR 0.475;95%CI:0.382,0.590)。
- 多个个体药物比较中IL23i较IL17i的PsA风险降低,但替拉珠单抗 vs 依奇珠单抗未达统计学显著。
核心结论
- 银屑病患者接受IL23i治疗后,后续发生PsA的风险低于接受IL17i治疗者。
研究设计与样本
- 回顾性队列研究,利用TriNetX数据库,将成年银屑病患者分为新处方IL23i(无IL17i暴露)与新处方IL17i(无IL23i暴露)两组,排除有PsA病史或既往使用抗TNF-α或抗IL-12/23药物者,共5490例患者经倾向评分1:1匹配后分析PsA风险,采用Cox回归计算风险比(HR)。
主要发现
- IL23i组5年PsA累积发生率为11.68%,IL17i组为19.94%,差异显著(P<0.001)。
- IL23i治疗与PsA风险降低相关(HR 0.475;95%CI:0.382,0.590)。
- 按年龄、性别、种族、银屑病亚型、肥胖及炎症标志物升高定义的各亚组中,风险降低持续存在。
- 个体药物比较:古塞奇尤单抗 vs 司库奇尤单抗(HR 0.480;95%CI:0.358,0.645)及 vs 依奇珠单抗(HR 0.698;95%CI:0.509,0.956)。
- 瑞莎珠单抗 vs 司库奇尤单抗(HR 0.433;95%CI:0.306,0.612)及 vs 依奇珠单抗(HR 0.504;95%CI:0.347,0.732);替拉珠单抗 vs 司库奇尤单抗(HR 0.339;95%CI:0.131,0.875)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Biologic therapies for skin psoriasis (PsO) have been linked to a lower risk of developing psoriatic arthritis (PsA), but their efficacy across different mechanisms of action remains to be fully explored. This study aimed to compare PsA risk in PsO patients prescribed IL-23 inhibitors (IL23i) vs IL-17 inhibitors (IL17i). METHODS: This retrospective cohort study utilized the TriNetX database to categorize adult PsO patients into two cohorts: those newly prescribed IL23i (without IL17i exposure) and those newly prescribed IL17i (without IL23i exposure). Patients with a history of PsA or previous use of anti-TNF-α or anti-IL-12/23 agents were excluded. A total of 5490 patients, matched 1:1 by propensity scores, were analysed for PsA risk using hazard ratios (HR) from Cox regression. RESULTS: The 5-year cumulative incidence of PsA was significantly lower in IL23i users compared with IL17i users (11.68% vs 19.94%; P < 0.001). IL23i treatment was associated with a reduced PsA risk (HR 0.475; 95% CI: 0.382, 0.590). This reduced risk persisted across various subgroups defined by age, sex, race, PsO subtypes, obesity and elevated inflammatory markers. Similar results were observed in individual drug comparisons, with lower risks for guselkumab vs secukinumab (0.480; 0.358, 0.645) and ixekizumab (0.698; 0.509, 0.956), risankizumab vs secukinumab (0.433; 0.306, 0.612) and ixekizumab (0.504; 0.347, 0.732), and tildrakizumab vs secukinumab (0.339, 0.131, 0.875). The comparison of tildrakizumab vs ixekizumab (0.451; 0.171, 1.191) also suggested a lower risk but was not statistically significant. CONCLUSION: PsO patients treated with IL23i had a lower subsequent PsA risk compared with those treated with IL17i.
引用
- Lin TL, Fan YH, Fan KS, et al. Psoriatic arthritis risk in psoriasis patients receiving anti-IL-23 vs anti-IL-17: comparison of drug classes and individual agents. Rheumatology (Oxford). 2026. PMID: 41105233. doi:10.1093/rheumatology/keaf489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。